Author

A. Yilma

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Approach:experimental assay· 2 Research Focus:host-pathogen & immune response· 2 Organism:mouse· 2 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

A. Garcia· 2 shared D. Quijada· 2 shared P. C. Karakousis· 2 shared P. Neupane· 2 shared S. Karanika· 2 shared A. Sher· 1 shared B. Shenkoya· 1 shared D. L. Costa· 1 shared

Activity by Year

2023-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 39 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersPharmacology & Toxicology

A. Garcia

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Pharmacological inhibition of macrophage triglyceride biosynthesis pathways does not improve Mycobacterium tuberculosis control in infected mice

J. R. Castillo, V. Guerrini, D. Quijada, S. Karanika, P. Neupane, H. Harris, A. Garcia, B. Shenkoya, A. Yilma, H. Bailey, R. Khan, M. Gopalakrishnan, M. L. Gennaro, P. C. Karakousis

This study evaluates two compounds that reduce triglyceride content in Mtb-infected macrophages but finds they do not reduce bacterial burden or inflammation in infected mice.

bioRxiv · Mar 6, 2024 · PreprintPharmacology & Toxicology

The heme oxygenase-1 metalloporphyrin inhibitor stannsoporfin enhances the bactericidal activity of a novel regimen for multidrug-resistant tuberculosis in a murine model

J. Ruelas Castillo, P. Neupane, S. Karanika, S. Krug, D. Quijada, A. Garcia, S. Ayeh, A. Yilma, D. L. Costa, A. Sher, N. Fotouhi, N. Serbina, P. C. Karakousis

This paper evaluates the adjunctive effect of the HO-1 inhibitor stannsoporfin in combination with a novel MDR-TB regimen in a murine model, showing reduced lung bacillary burden but no effect on microbiological relapse.

bioRxiv · Aug 9, 2023Microbiology